NEW PRAGUE, Minn. / Jul 29, 2025 / Business Wire / Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Company management will participate in the Canaccord Genuity 45th Annual Growth Conference, which will be held August 12-14, 2025 in Boston, MA. Electromed President and Chief Executive Officer Jim Cunniff, and Chief Financial Officer Brad Nagel will present on Tuesday, August 12 at 12:30 pm ET. Interested parties may access a live webcast of the presentation using the following link: Electromed CG Presentation. The link will also be posted on the Electromed Investor Relations website under Events & Presentations.
Institutional investors may request one-on-one meetings through Canaccord Genuity.
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
| Last Trade: | US$24.10 |
| Daily Change: | -1.17 -4.63 |
| Daily Volume: | 44,793 |
| Market Cap: | US$201.960M |
August 26, 2025 April 03, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
